A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.
Somaiah N, Chawla SP, Block MS, Morris JC, Do K, Kim JW, Druta M, Sankhala KK, Hwu P, Jones RL, Gnjatic S, Kim-Schulze S, Tuballes K, Yishak M, Lu H, Yakovich A, Ter Meulen J, Chen M, Kenney RT, Bohac C, Pollack SM.
Somaiah N, et al. Among authors: bohac c.
Oncoimmunology. 2020 Nov 19;9(1):1847846. doi: 10.1080/2162402X.2020.1847846.
Oncoimmunology. 2020.
PMID: 33312760
Free PMC article.
Clinical Trial.